FDA reviews Jardiance as cardiovascular diabetes treatment
January 27, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, jardiance
The FDA has accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for their diabetes drug Jardiance to be …
Alliance Pharmaceuticals appoints new head of international business
January 27, 2016Medical Communications, Sales and Marketing Alliance Pharmaceuticals
Alliance Pharmaceuticals has appointed Karim Husny as head of international business- a role in which he will support all Alliance …
NICE recommends six drugs in final guidance
January 27, 2016Research and Development, Sales and Marketing NHS, NICE
NICE has published final recommendations approving drug treatments for ovarian cancer, prostate cancer, multiple myeloma, gastric cancer and idiopathic pulmonary …
Johnson & Johnson hit by fall in 2015 sales
January 27, 2016Research and Development, Sales and Marketing Janssen, Johnson and Johnson, financial results, revenue, sales
Full year sales at the healthcare giant Johnson & Johnson fell by 6% in 2015, to just over $70 billion, …
NICE backs biosimilars with arthritis drug endorsements
January 27, 2016Research and Development, Sales and Marketing DMARDs, NICE, biosimilars, rheumatoid arthritis
NICE has published updated final guidance recommending seven biological disease modifying drugs (DMARDs) for treatment of severe rheumatoid arthritis which …
FDA to review Amgen’s Humira biosimilar
January 26, 2016Manufacturing and Production ABP-501, Amgen, FDA, biosimilar
The FDA has accepted for review Amgen’s Biologics License Application (BLA) for ABP 501, a biosimilar candidate to AbbVie’s Humira …
Post-sanctions Iran attracts pharma investment
January 26, 2016Manufacturing and Production, Sales and Marketing Gulf Co-operation Council, Iran, Isral, Saudi Arabia, United Arab Emirates, middle east
Just a few days have passed since decade-long economic sanctions on Iran were lifted, as the middle-eastern powerhouse agreed to …
GSK and Sanofi considering developing Zika vaccine
January 26, 2016Manufacturing and Production GSK, Sanofi, World Health Organisation, Zika virus, microcephaly
Pharma companies Sanofi and GSK are reviewing the possibility of using their respective inoculation technologies to develop a vaccine for …
UK Government commits £1 billion to malaria fight
January 26, 2016Manufacturing and Production Bill Gates, Chancellor, George Osborne, Ross Fund, infectious diseases, malaria
Chancellor George Osborne has set out details of a billion pound fund to develop, test and produce new products to …
Shire tries again with lifitegrast dry eye FDA application
January 25, 2016Manufacturing and Production, Sales and Marketing FDA, Shire, dry eye disease, lifitegrast
Shire has resubmitted its New Drug Application (NDA) to the US FDA for its rejected dry eye syndrome drug lifitegrast. …
Avacta appoints Philippe Cotrel as chief commercial officer
January 25, 2016Manufacturing and Production, Research and Development Avacta
Cotrel joins Avacta from Abcam, where he held the role of commercial operations director.He will lead the Group’s commercial strategy …
New chief exec at MannKind
January 25, 2016Manufacturing and Production, Research and Development, Sales and Marketing Alfred Mann, Duane DeSisto, Insulet, Mannkind, Matthew Pffefer
The board of directors of MannKind have appointed Matthew Pfeffer as chief executive of MannKind.He replaces Alfred Mann who has …
AbbVie VP joins UCB Pharma
January 25, 2016Manufacturing and Production, Research and Development, Sales and Marketing Pascale Richetta, UCB, UCB Pharma
Pascale Richetta will join the UCB as its new head of the bone therapy patient value unit as from February …
Cancer Research UK appoints Professor Sir Bruce Ponder as trustee
January 25, 2016Research and Development Cancer Research UK, Professor Sir Bruce Ponder
Cancer Research UK has appointed Professor Sir Bruce Ponder as a trustee. Ponder is emeritus professor of oncology at Cambridge …
Amgen earns first Japanese nod for PCSK9 inhibitor
January 25, 2016Sales and Marketing Amgen, Astellas, Japan, PCSK9 inhibitor, Repatha, evolocumab, high cholesterol
The Japanese Ministry of Health, Labour and Welfare has approved Amgen’s cholesterol-lowering medication Repatha, in a joint venture between Amgen …
The case for leaders with scientific acumen in pharma
January 25, 2016Medical Communications, Research and Development research and development
Pharmaceutical companies are currently undergoing fundamental, disruptive changes to conventional research and development models. This is in an attempt to …
Big pharma and UK universities launch £40m innovation fund
January 25, 2016Research and Development, Sales and Marketing Apollo, AstraZeneca, GSK, GlaxoSmithKline, Johnson & Johson, UCL, University College London, University of Cambridge, collaboration, imperial college london, joint venture
A consortium of big pharma companies and university with world-leading medical research facilities is to invest £40 million, to “significantly …
Researchers raise TPP legislation concerns
January 25, 2016Manufacturing and Production, Sales and Marketing Legislation, Trans-Pacific Partnership, tpp, trade agreement
Academics have warned that global trade regulations under consideration by the US and other countries could prevent access to medicines …
FDA approves new uses for BMS’ Opdivo/Yervoy cancer combo
January 25, 2016Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilimumabm melanoma, nivolumab, opdivo, skin cancer
The FDA has granted Bristol Myers Squibb an expanded indication for its two-cancer drug regimen Opdivo and Yervoy, to treat …
AbbVie and MD Anderson in cancer research partnership
January 25, 2016Research and Development, Sales and Marketing AbbVie, MD Anderson Cancer Centre, immuno-oncology
AbbVie has announced a new partnership with The University of Texas MD Anderson Cancer Centre, using its immunotherapy platform to …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
